Asthma management: The case for aiming at control rather than merely relief

Postgraduate Medicine

Volumn 103, Issue 3, 1998, Pages 53-69

  Keenan, Joseph M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; NEDOCROMIL; NEDOCROMIL SODIUM; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; DIAGNOSTIC ACCURACY; DISEASE CONTROL; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION;

EID: 0031934388     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1998.03.416     Document Type: Article

References (39)

1. Centers for Disease Control and Prevention. Asthma mortality and hospitalization among children and young adults: United States, 1980-1993. MMWR 1996; 45(17):350-3
2. Adams PF, Marano MA. Current estimates from the National Health Interview Survey. Vital Health Stat 1995;10:94
3. Burt CW, Knapp DE. Ambulatory care visits for asthma: United States, 1993-94. Advance data from Vital and Health Statistics of the Centers for Disease Control and Prevention/National Center for Health Statistics. Hyattsville, Md: Dept of Health and Human Services, 1996; No. 217:1-18
4. Zeiger RS, Heller S, Mellon MH, et al. Facilitated referral to asthma specialist reduces relapses in asthma emergency room visits. J Allergy Clin Immunol 1991;87(6): 1160-8 [Erratum, J Allergy Clin Immunol 1992;90(2):278]
5. Freund DA, Stein J, Hurley R, et al. Specialty differences in the treatment of asthma. J Allergy Clin Immunol 1989; 84(3):401-6
6. Charlton I, Jones K, Bain J. Delay in diagnosis of childhood asthma and its influence on respiratory consultation rates. Arch Dis Child 1991;66(5):633-5
7. Jones KP, Charlton IH, Middleton M, et al. Targeting asthma care in general practice using a morbidity index. BMJ 1992;304(6838):1353-6
8. National Asthma Education Program expert panel report. Guidelines for the diagnosis and management of asthma. Bethesda: Dept of Health and Human Services, 1991; NIH publication No. 91-3042
9. National Asthma Education Program expert panel report. Executive summary: guidelines for the diagnosis and management of asthma. Bethesda: Dept of Health and Human Services, 1991; NIH publication No. 91-3042A
10. National Heart, Lung, and Blood Institute. Global initiative for asthma. 1995; DHHS publication No. 95-3659
11. Kendrick AH, Higgs CM, Whitfield MJ, et al. Accuracy of perception of severity of asthma: patients treated in general practice. BMJ 1993;307(6901):422-4
12. Krahn M. Issues in the cost-effectiveness of asthma education. Chest 1994; 106(4 Suppl):264-9S
13. Ignacio-Garcia JM, Gonzalez-Santos P. Asthma self-management education program by home monitoring of peak expiratory flow. Am J Respir Crit Care Med 1995;151(2 Pt 1):353-9
14. National Analysts. Asthma agent survey. Philadelphia: Booz-Allen & Hamilton, Inc, 1990
15. Bone RC. A step care strategy for asthma management. J Respir Dis 1988; 9:104-17
16. Lang DM. Inhaled steroids are under-utilized in urban areas of high asthma mortality. (Abstr) J Allergy Clin Immunol 1994;93:246
17. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma: report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis 1993; 148(4 Pt 2):S1-26
18. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142(4):832-6
19. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997;126(3):177-83
20. Kaliner MA. Inhaled corticosteroids for chronic asthma. Am Fam Physician 1990;42:1609-16
21. Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;277(9):722-7
22. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98(2):196-208
23. Suissa S, Biais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994;7(9):1602-9
24. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996;335(12):841-7
25. Aubier M. Effect of theophylline on diaphragmatic and other skeletal muscle function. J Allergy Clin Immunol 1986; 78(4 Pt 2):787-92
26. Sullivan P, Bekir S, Jaffar Z, et al. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343(8904):1006-8 [Erratum, Lancet 1994;343(8911):1512]
27. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996; 334(21):1380-8
28. Finnerty JP, Wood-Baker R, Thomson H, et al. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992; 145(4 Pt 1):746-9
29. Taylor IK, O'Shaughnessy KM, Fuller RW, et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337(8743);690-4
30. 4-receptor antagonist, ICI 204,219, on cold-air-induced broncho-constriction in patients with asthma. (Abstr) J Allergy Clin Immunol 1994; 93:295
31. Calhoun WJ, Lavins BJ, Glass M. Effect of 'Accolate' (zafirlukast) on bronchoalveolar lavage fluid (BAL) after segmental bronchoprovocation (SBP) in patients with mild to moderate asthma. (Abstr) Am J Respir Crit Care Med 1995; 151:A42
32. ACCOLATE Asthma Trialists Group. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150(3):618-23
33. Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996; 275(12):931-6
34. Spector SL. Leukotriene inhibitors and antagonists in asthma. Ann Allergy Asthma Immunol 1995;75(6 Pt 1):463-70, 473; quiz 473-4
35. Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98(3):528-34
36. Lichey J, Hummel S, Beck E, et al. Effect of leukotriene antagonist Bay X 1005 versus placebo in patients with severe steroid dependent bronchial asthma. (Abstr) Am J Respir Crit Care Med 1995;151:A377
37. Yeung M, O'Connor SA, Parry DT, et al. Compliance with prescribed drug therapy in asthma. Respir Med 1994; 88(1):31-5
38. Allegra L. Deliberate non-compliance due to dislike of medication. Eur Respir Rev 1995;5:170-2
39. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154(12): 1349-52